Endpoints News
@endpts.com
We're where the business of medicine gets answers. An independent news media organization covering biotech, pharma, science, policy, finance, venture capital and markets, and how they drive the life sciences industry. Read us at www.endpts.com.
How’s biopharma feeling heading into 2026? We asked everyone at Endpoints at #JPM26 — and the answers land somewhere between breakthrough and cautious optimism.
Follow the latest from San Francisco in our live blog: endpoints.news/jpm26-day-3-...
Follow the latest from San Francisco in our live blog: endpoints.news/jpm26-day-3-...
January 14, 2026 at 9:42 PM
How’s biopharma feeling heading into 2026? We asked everyone at Endpoints at #JPM26 — and the answers land somewhere between breakthrough and cautious optimism.
Follow the latest from San Francisco in our live blog: endpoints.news/jpm26-day-3-...
Follow the latest from San Francisco in our live blog: endpoints.news/jpm26-day-3-...
Endpoints reporters wrapped up our Main Stage programming with a roundtable on the regulatory environment, China, and everything else they're watching for the year ahead.
Thanks so much for joining us at the Endpoints at #JPM26 event. Keep following along for more of our coverage out of JPM.
Thanks so much for joining us at the Endpoints at #JPM26 event. Keep following along for more of our coverage out of JPM.
January 13, 2026 at 9:11 PM
Endpoints reporters wrapped up our Main Stage programming with a roundtable on the regulatory environment, China, and everything else they're watching for the year ahead.
Thanks so much for joining us at the Endpoints at #JPM26 event. Keep following along for more of our coverage out of JPM.
Thanks so much for joining us at the Endpoints at #JPM26 event. Keep following along for more of our coverage out of JPM.
Live from Endpoints at #JPM26: Nobel Laureate Fred Ramsdell worries that the US is ceding its leadership position on cell therapy to China. "I think we risk losing that if we don't continue to invest in this field." Join us virtually for the rest of the day’s programming: events.endpoints.news/jpm26
January 13, 2026 at 7:00 PM
Live from Endpoints at #JPM26: Nobel Laureate Fred Ramsdell worries that the US is ceding its leadership position on cell therapy to China. "I think we risk losing that if we don't continue to invest in this field." Join us virtually for the rest of the day’s programming: events.endpoints.news/jpm26
The pharmaceutical industry is slow by nature, Novo Nordisk CEO Mike Doustdar said at the Endpoints at #JPM26 event this morning. But he thinks it can get faster.
January 12, 2026 at 6:11 PM
The pharmaceutical industry is slow by nature, Novo Nordisk CEO Mike Doustdar said at the Endpoints at #JPM26 event this morning. But he thinks it can get faster.
What does Big Pharma really think of the UK? @financialtimes.com global pharmaceutical editor Hannah Kuchler joins us to break down how drugmakers are operating across the pond. Live today at 11 AM ET.
endpoints.news/post-hoc-liv...
endpoints.news/post-hoc-liv...
November 4, 2025 at 2:11 PM
What does Big Pharma really think of the UK? @financialtimes.com global pharmaceutical editor Hannah Kuchler joins us to break down how drugmakers are operating across the pond. Live today at 11 AM ET.
endpoints.news/post-hoc-liv...
endpoints.news/post-hoc-liv...
Health tech is attracting capital and defying the downturn: from wearable tech to RWE, momentum is building. Join our online sessions in the morning, and in the evening we’re live in person with a reception at NYC’s Book Club Bar. Get your spot: events.endpoints.news/healthtech20...
October 28, 2025 at 6:13 PM
Health tech is attracting capital and defying the downturn: from wearable tech to RWE, momentum is building. Join our online sessions in the morning, and in the evening we’re live in person with a reception at NYC’s Book Club Bar. Get your spot: events.endpoints.news/healthtech20...
Tomorrow: ESMO 2025 delivered pivotal cancer trial data. Join Endpoints for strategic analysis of what matters most. Register to watch: events.endpoints.news/esmo2025/reg...
October 21, 2025 at 6:06 PM
Tomorrow: ESMO 2025 delivered pivotal cancer trial data. Join Endpoints for strategic analysis of what matters most. Register to watch: events.endpoints.news/esmo2025/reg...
Health tech is taking center stage — from wearables to RWE shaping pharma’s future. Join us Nov. 6 for online sessions in the morning, then meet us in person for a reception at NYC’s Book Club Bar. Seats are limited — reserve your spot now: events.endpoints.news/healthtech20...
October 16, 2025 at 6:03 PM
Health tech is taking center stage — from wearables to RWE shaping pharma’s future. Join us Nov. 6 for online sessions in the morning, then meet us in person for a reception at NYC’s Book Club Bar. Seats are limited — reserve your spot now: events.endpoints.news/healthtech20...
Meet our winners of the Endpoints 11! Last week, we announced the honorees at our annual gala in Boston—handpicked by our newsroom. They represent the best and brightest in biotech, and we'll be following every step. Congratulations! endpoints.news/the-2025-win...
September 22, 2025 at 2:53 PM
Meet our winners of the Endpoints 11! Last week, we announced the honorees at our annual gala in Boston—handpicked by our newsroom. They represent the best and brightest in biotech, and we'll be following every step. Congratulations! endpoints.news/the-2025-win...
Umoja Biopharma: endpoints.news/endpoints-11...
September 19, 2025 at 2:21 PM
Umoja Biopharma: endpoints.news/endpoints-11...
Third Arc Bio: endpoints.news/endpoints-11...
September 19, 2025 at 2:21 PM
Third Arc Bio: endpoints.news/endpoints-11...
Stylus Medicines: endpoints.news/endpoints-11...
September 19, 2025 at 2:21 PM
Stylus Medicines: endpoints.news/endpoints-11...
Sironax: endpoints.news/endpoints-11...
September 19, 2025 at 2:21 PM
Sironax: endpoints.news/endpoints-11...
Orbis Medicines: endpoints.news/endpoints-11...
September 19, 2025 at 2:21 PM
Orbis Medicines: endpoints.news/endpoints-11...
Lila Sciences: endpoints.news/endpoints-11...
September 19, 2025 at 2:21 PM
Lila Sciences: endpoints.news/endpoints-11...
Judo Bio: endpoints.news/endpoints-11...
September 19, 2025 at 2:21 PM
Judo Bio: endpoints.news/endpoints-11...
Dispatch Biotherapeutics: endpoints.news/endpoints-11...
September 19, 2025 at 2:21 PM
Dispatch Biotherapeutics: endpoints.news/endpoints-11...
Chai Discovery: endpoints.news/endpoints-11...
September 19, 2025 at 2:21 PM
Chai Discovery: endpoints.news/endpoints-11...
Candid Therapeutics: endpoints.news/endpoints-11...
September 19, 2025 at 2:21 PM
Candid Therapeutics: endpoints.news/endpoints-11...
Averna Therapeutics: endpoints.news/endpoints-11...
September 19, 2025 at 2:21 PM
Averna Therapeutics: endpoints.news/endpoints-11...
Endpoints News returns to Boston’s State Room to announce the 2025 class of biotechs worth watching. Join the live unveiling and see the industry’s next chapter come into focus. Which biotechs will make the leap? Get your ticket today to save with Early Bird: events.endpoints.news/eleven25/883...
August 21, 2025 at 9:27 PM
Endpoints News returns to Boston’s State Room to announce the 2025 class of biotechs worth watching. Join the live unveiling and see the industry’s next chapter come into focus. Which biotechs will make the leap? Get your ticket today to save with Early Bird: events.endpoints.news/eleven25/883...
RFK Jr.'s mRNA funding cuts aren't justified, Admiral Brett Giroir, former US bio-preparedness official, said on Post-Hoc Live. "I thought the whole premise was wrong. The facts that were stated were not facts at all."
August 13, 2025 at 5:55 PM
RFK Jr.'s mRNA funding cuts aren't justified, Admiral Brett Giroir, former US bio-preparedness official, said on Post-Hoc Live. "I thought the whole premise was wrong. The facts that were stated were not facts at all."
The mood in biopharma this quarter hasn’t been great — and the chaotic policy environment isn’t helping, said BMO's Evan Seigerman on Post-Hoc Live Thursday. He joined the show to take stock of Q2 earnings and look ahead to what comes next.
August 8, 2025 at 6:08 PM
The mood in biopharma this quarter hasn’t been great — and the chaotic policy environment isn’t helping, said BMO's Evan Seigerman on Post-Hoc Live Thursday. He joined the show to take stock of Q2 earnings and look ahead to what comes next.
In case you missed it – Varda Space Industries' CSO Adrian Radocea came to Post-Hoc Live last week to discuss what happens when drugs are formulated in orbit, and come back down to earth. Watch it here: www.youtube.com/live/sZ_Ow1d...
July 21, 2025 at 12:48 PM
In case you missed it – Varda Space Industries' CSO Adrian Radocea came to Post-Hoc Live last week to discuss what happens when drugs are formulated in orbit, and come back down to earth. Watch it here: www.youtube.com/live/sZ_Ow1d...